

---

## Research Paper

---

# Intravenous Hydrophobic Drug Delivery: A Porous Particle Formulation of Paclitaxel (AI-850)

Julie A. Straub,<sup>1,3</sup> Donald E. Chickering,<sup>1</sup> Jonathan C. Lovely,<sup>1</sup> Huimin Zhang,<sup>1</sup> Bhavdeep Shah,<sup>1</sup> William R. Waud,<sup>2</sup> and Howard Bernstein<sup>1</sup>

Received September 28, 2004; accepted December 13, 2004

**Purpose.** To develop a rapidly dissolving porous particle formulation of paclitaxel without Cremophor EL that is appropriate for quick intravenous administration.

**Methods.** A rapidly dissolving porous particle formulation of paclitaxel (AI-850) was created using spray drying. AI-850 was compared to Taxol following intravenous administration in a rat pharmacokinetic study, a rat tissue distribution study, and a human xenograft mammary tumor (MDA-MB-435) model in nude mice.

**Results.** The volume of distribution and clearance for paclitaxel following intravenous bolus administration of AI-850 were 7-fold and 4-fold greater, respectively, than following intravenous bolus administration of Taxol. There were no significant differences between AI-850 and Taxol in tissue concentrations and tissue area under the curve (AUC) for the tissues examined. Nude mice implanted with mammary tumors showed improved tolerance of AI-850, enabling higher administrable doses of paclitaxel, which resulted in improved efficacy as compared to Taxol administered at its maximum tolerated dose (MTD).

**Conclusions.** The pharmacokinetic data indicate that paclitaxel in AI-850 has more rapid partitioning from the bloodstream into the tissue compartments than paclitaxel in Taxol. AI-850, administered as an intravenous injection, has been shown to have improved tolerance in rats and mice and improved efficacy in a tumor model in mice when compared to Taxol.

**KEY WORDS:** drug delivery; hydrophobic drugs; microparticles; paclitaxel; spray drying.

## INTRODUCTION

The poor aqueous solubility of hydrophobic drugs is a challenging formulation problem, particularly for intravenous delivery (1). It is estimated that 40% of new chemical entities have poor aqueous solubility (2). Poor aqueous solubility is, in particular, a common property of compounds identified using combinatorial chemistry and high-throughput screening (3). Thus, creating intravenous formulations of such compounds is of significant value. Paclitaxel, the active ingredient in the commercially available anticancer agent Taxol (paclitaxel injection, Bristol-Myers Squibb Oncology, Princeton, NJ, USA), has low aqueous solubility (4). Taxol consists of paclitaxel dissolved in Cremophor EL (BASF, Ludwigshafen, Germany; polyoxyethylated castor oil) and ethanol. Side effects observed with the intravenous administration of Taxol such as hypersensitivity reactions, nephrotoxicity, and neurotoxicity have been attributed to Cremophor (5). Due to such reactions, patients must be premedicated with corticosteroids and antihistamines, and Taxol must be administered as a 1–24 h infusion (6–7). Taxol is an important treatment of breast, ovarian, and non-small cell lung carcinomas (8–9), and modified formulations of paclitaxel that do not contain Cremophor

are currently of significant interest (10–12). A number of nanoparticle- and microparticle-based formulations of paclitaxel, and related formulations such as liposomes and emulsions, have been reported in the literature (13–21). In these formulations, the paclitaxel is encapsulated within another material such as a hydrophobic polymer like poly (lactide *co*-glycolide) (PLGA), a protein, or lipids. These types of materials create a sustained-release system for paclitaxel with drug release occurring over hours to months. The porous particle formulation of paclitaxel (AI-850) discussed in this paper was developed with the goal of creating a rapidly dissolving formulation that could be administered as an i.v. bolus or a short infusion.

Acusphere's hydrophobic drug delivery system (HDDS), consisting of sub-micrometer to micrometer size porous particles, can be used to create rapidly dissolving formulations of hydrophobic drugs (22–25). The porous particles consist of drug microparticles and sub-micrometer particles and a water-soluble excipient such as a sugar or amino acid. During reconstitution, the water-soluble excipient dissolves, leaving a suspension of drug microparticles and sub-micrometer particles that dissolve upon further dilution in the plasma. The porous nature of the particles facilitates wetting and rapid dissolution of the encapsulated drug.

The production of the porous particles involves spray drying a solution containing the drug, the water-soluble excipient, and a pore-forming agent (i.e., a volatile salt). The

<sup>1</sup> TAcusphere, Inc., Watertown, Massachusetts 02472, USA.

<sup>2</sup> Southern Research Institute, Birmingham, Alabama 35205, USA.

<sup>3</sup> To whom correspondence should be addressed. (e-mail: julie.straub@acusphere.com)

pore-forming agent is volatilized along with the process solvent during the spray drying to produce a porous matrix comprising drug microparticles and the excipient. The water-soluble excipient facilitates wetting of the drug particles during reconstitution, provides proper osmolality to the dosage form, and improves the storage stability of the dry powder. The spray-drying process can be performed aseptically, and the resulting particles are in the appropriate size range for i.v. administration following reconstitution, as well as appropriate for administration by other parenteral routes, oral administration, and pulmonary administration.

This paper discusses the application of the hydrophobic drug delivery system to a rapidly dissolving formulation of paclitaxel for intravenous administration as an i.v. bolus or a short infusion and which would not require premedication of the patients with corticosteroids and antihistamines.

## MATERIALS AND METHODS

### Production of Microparticles

A paclitaxel-containing solution was prepared by dissolving paclitaxel (6.25 mg/ml), polysorbate 80 (0.625 mg/ml), and polyvinylpyrrolidone C15 (0.625 mg/ml) in ethanol. An aqueous solution was prepared containing the pore-forming agent (22), ammonium bicarbonate, at 2.5 mg/ml, and mannitol at 25 mg/ml. The aqueous solution was added to the ethanol solution in a ratio of 1:4. The resulting solution was spray dried on a spray dryer custom-designed to operate aseptically. The spray dryer was made from 316 stainless steel components with tri-clamp connections. The system was run under positive pressure with sterile-filtered nitrogen gas for the drying gas and atomization gas. A 0.22- $\mu$ m filter was installed on the exhaust to maintain sterility and to capture any paclitaxel particulates that escape the spray-dryer cyclone.

The spray dryer used an internal mixing air-atomizing nozzle (the internal diameter of the fluid cap was 0.028", and the internal diameter of the air cap was 0.060") and nitrogen as the drying gas. Spray-drying conditions were as follows: 75 ml/min solution flow rate, 154 L/min atomization gas rate, 120 kg/h drying gas rate, 116°C inlet temperature, and 62°C outlet temperature. The resulting powder was collected, filled into glass vials, and stored at 2–8°C.

### Paclitaxel Potency and Purity Analysis

For potency and purity analysis, AI-850 was dissolved in methanol:water:acetic acid (85:15:1) and analyzed by HPLC using an Agilent 1100 Series high pressure liquid chromatography (HPLC) (Agilent Technologies Inc., Palo Alto, CA, USA). Chromatographic conditions used for the analysis of paclitaxel used UV detection at 230 nm and a Phenomenex Curosil PFP column (5  $\mu$ m, 250  $\times$  4.6 mm) held at 35°C during analysis. The mobile phases used were A (acetonitrile:water, 35:65) and B (acetonitrile:water, 75:25), with a gradient running from 100% A to 85% A over 12 min, followed by a gradient running from 85% A to 0% A over the next 11.5 min. A flow rate of 1.5 ml/min was used. Potency values were obtained via comparison to a reference standard obtained from Hauser Laboratories (Boulder, CO, USA) and are based on 100% potency being the theoretical loading of the AI-850 powder based on the composition spray dried.

### Differential Scanning Calorimetry (DSC)

DSC analyses were carried out on a TA 2920 differential scanning calorimeter (TA Instruments, New Castle, DE, USA) using nitrogen as the purge gas. Indium metal was used as the calibration standard. The samples were heated on the DSC at a heating rate of 10°C/min to a final temperature of 350°C.

### Dry Powder Particle Size Analysis

Particle size analysis of AI-850 powder (prior to reconstitution) was performed using a Malvern Mastersizer (Malvern Instruments Ltd., Worcester, England) fitted with a dry powder module at a pressure of 65 psi.

### Particle Size Analysis Post-Reconstitution

Particle size analysis of paclitaxel particles in AI-850 post-reconstitution was performed using a Multisizer II (Beckman Coulter Inc., Fullerton, CA, USA) equipped with a 50- $\mu$ m aperture. The electrolyte used for the analysis contained sodium chloride (9 mg/ml), monobasic sodium phosphate monohydrate (0.19 mg/ml), anhydrous dibasic sodium phosphate (1.95 mg/ml), mannitol (55 mg/ml), polyvinylpyrrolidone K15 (5.5 mg/ml), and was adjusted to pH 7.4 with 0.1 N HCl. The electrolyte solution was presaturated with paclitaxel immediately prior to use by addition of a solution of paclitaxel in methanol (35 mg paclitaxel/ml methanol; 4 ml to 1 L of modified electrolyte), followed by filtration through an 0.22- $\mu$ m cellulose acetate filter to remove excess (precipitated) paclitaxel. The electrolyte was saturated with paclitaxel to ensure the paclitaxel particles in AI-850 did not dissolve upon dilution into the electrolyte for analysis. The presence of mannitol and polyvinylpyrrolidone K15 in the electrolyte was found to suppress crystallization of paclitaxel from the paclitaxel-saturated electrolyte. The paclitaxel-saturated electrolyte was analyzed by Coulter Multisizer analysis prior to use for analysis of AI-850 suspensions to ensure that no significant crystallization of paclitaxel had occurred in the electrolyte solution. Suspensions of AI-850 were added to the paclitaxel-saturated electrolyte for analysis.

### Microscopy

For transmission electron microscopy (TEM), AI-850 powder was embedded in a LR White Resin, which was then cut into thin (100–120 nm) sections on a diamond knife, and the sections were imaged on a Zeiss EM-10 transmission electron microscope (Zeiss Group, Jena, Germany) at 60 kV.

For scanning electron microscopy (SEM), the particles were sputter coated with platinum-palladium (80:20) and then imaged on a Hitachi S-4800 or a Hitachi S-2700 (Hitachi High Technologies America, Inc., San Jose, CA, USA).

For scanning electron microscopy (SEM) of paclitaxel particles post-reconstitution, the suspension post-reconstitution was filtered using an 0.22- $\mu$ m filter, and the paclitaxel particles retained on the filter were rinsed with water and vacuum dried prior to sputter coating.

### In Vitro Dissolution Analysis

Dissolution studies were conducted in PBS containing 0.08% Tween 80 (T80/PBS). T80/PBS (10 ml) was added to

an appropriate amount of material being tested to contain 5 mg of paclitaxel in a 15 ml polypropylene conical tube, and the suspension was vortexed to create a suspension of micro-particles of paclitaxel. The suspension (0.25 ml) was then added to 250 ml of T80/PBS in a 600 ml glass beaker for dissolution analysis. Samples (1–2 ml) were removed and immediately filtered at each time-point. HPLC analysis was performed directly on the filtered aqueous solutions using an Agilent 1100 Series HPLC (Agilent Technologies Inc.). Chromatographic conditions used for the analysis of dissolution of paclitaxel used a Nucleosil column (5  $\mu$ m, C18, 100A, 250  $\times$  4.6 mm), a mobile phase of 2 mM H<sub>3</sub>PO<sub>4</sub>/acetonitrile (2:3) at a flow rate of 1.5 ml/min, UV detection at 227 nm, and a run time of 25 min. The concentration of paclitaxel in the dissolution media was 0.5  $\mu$ g/ml. The saturation concentration observed for paclitaxel in T80/PBS was observed to be 1.5  $\mu$ g/ml, and thus the dissolution assay was performed at a concentration lower than the saturation concentration of paclitaxel in the dissolution media.

#### Animal Care

In the three animal studies described below, cage size and animal care conformed to the guidelines of the *Guide for the Care and Use of Laboratory Animals*, 7th Edition (National Research Council, National Academy Press, Washington, DC, 1996), and the U.S. Department of Agriculture through the Animal Welfare Act (Public Law 99-198).

#### Pharmacokinetic Study of Paclitaxel in Rats

Male and female Sprague-Dawley rats (3/sex per group; animals were 8–11 weeks of age) were assigned to one of eight groups. Two groups received an i.v. bolus of Taxol (5 mg/kg or 10 mg/kg). Two groups received a 3 h i.v. infusion of Taxol (5 mg/kg or 10 mg/kg of paclitaxel). Four groups received an i.v. bolus of AI-850 (5 mg/kg, 10 mg/kg, 20 mg/kg, or 30 mg/kg of paclitaxel). AI-850 was reconstituted with water and diluted with D5W for dosing at a paclitaxel concentration of 10 mg/ml. Taxol was diluted with sterile saline for dosing at a paclitaxel concentration of 1 mg/ml.

Serial blood samples (0.3 ml) were taken during 24 h and processed into plasma. For the bolus dose groups, blood samples were collected at 0 min (pre-dose), 5 and 30 min, and at 1, 2, 3, 5, 8, 12, and 24 h after dosing. For the infusion groups, blood samples were collected at 0 min (pre-infusion) and at the following time-points after the start of the infusion: 30 min, and at 1, 2, 3, 4, 5, 8, 12, and 24 h. The plasma samples were analyzed for paclitaxel using a validated liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) assay at Southern Research Institute. The pharmacokinetic parameters were calculated assuming a two-compartment analysis using WinNonlin software.

#### Tissue Distribution Study of Paclitaxel in Rats

Single doses of either AI-850 or Taxol were administered intravenously via tail vein to groups of 18 male Sprague-Dawley rats/group. Animals were 8–9 weeks of age. The paclitaxel dose was 5.7 mg/kg for both formulations. AI-850 was reconstituted with water and diluted into D5W to a paclitaxel concentration of 6.9 mg/ml for administration. Taxol Injection was diluted with saline to a final paclitaxel concentration of 1.0 mg/ml for administration. Samples of plasma and selected

tissues were collected from three rats/group at 0.5, 1, 2, 5, 12, and 24 h post-dose. The following tissues were collected and flash-frozen in liquid nitrogen: adrenal glands, brain, bone marrow, heart, kidney, liver, lung, muscle (back), small intestine (duodenum), sciatic nerve, spleen, testes, and thymus. Plasma and tissue samples were analyzed for concentrations of paclitaxel using a validated LC/MS/MS method (tissue samples were homogenized prior to analysis) at Southern Research Institute. Mean tissue paclitaxel concentration data were subjected to pharmacokinetic analyses using WinNonlin software. Values of AUC (area under the curve) were calculated using the trapezoidal rule. Plasma paclitaxel concentration data were fit to a compartmental model.

#### In Vivo Antitumor Efficacy Study in Mice

Mice were young (approximately 23 g), adult, female athymic NCr-Nu (14 mice/group). Mice were implanted subcutaneously with 30–40 mg fragments of the human mammary tumor MDA-MB-435 on day 0 (26). Treatment was scheduled to begin when the tumors ranged in size from 75 to 150 mg. Three groups were treated with AI-850 (15 mg/kg, 30 mg/kg, or 40 mg/kg of paclitaxel), one group was treated with the maximum tolerated dose (MTD) of Taxol (27) in this model (15 mg/kg of paclitaxel), and one control group was treated with D5W. AI-850 was reconstituted with 5% dextrose (D5W) to paclitaxel concentrations of 1.5 mg/ml, 3 mg/ml, and 4 mg/ml. Taxol was diluted with saline to a paclitaxel concentration of 1.5 mg/ml. Agents were administered via i.v. injection into the tail vein, once a day for 5 days. Mice were observed for survival, tumor size, and body weight. Tumors were measured by caliper in two dimensions and converted to tumor mass using the formula for a prolate ellipsoid ( $1 \times w^2/2$ ).

Antitumor activity was assessed by the delay in tumor growth of the treated groups in comparison to the vehicle-treated control. The values for the time required for two tumor mass doublings (four times the original size) and t-c were calculated. The value of t-c (days) is the difference in the median of times post-implant for tumors of the treated groups to attain an evaluation size compared to the median of the control group. The time required for tumor mass doubling is calculated based on the initial tumor weight at the beginning of the treatment period, and values between measurements are calculated by exponential extrapolation.

## RESULTS

#### Analysis of Paclitaxel Within AI-850

AI-850 was made via spray drying an ethanol-water solution containing paclitaxel, ammonium bicarbonate (the pore-forming agent), mannitol, polysorbate 80, and polyvinylpyrrolidone C15. As expected for a spray-drying process, paclitaxel encapsulation efficiency was essentially 100%, with observed values of chromatographic potency of 99.8%  $\pm$  1.5% (n = 6 lots). The chromatographic purity of paclitaxel in AI-850 was comparable to the purity of the starting bulk paclitaxel, indicating that the paclitaxel molecule was stable to the processing conditions. For example, the chromatographic purity of the paclitaxel for both the starting raw material and the lot of AI-850 used in the tissue distribution study were observed to be 99.5%. DSC analysis indicated that the paclitaxel within AI-850 was amorphous.




Fig. 1. Dry powder particle size distribution of AI-850 as analyzed on the Malvern Mastersizer.

### Particle Characteristics

The mean particle size for AI-850 prior to reconstitution was  $1.53 \mu\text{m} \pm 0.07 \mu\text{m}$  ( $n = 6$  lots). A dry powder particle size distribution from a representative lot is shown in Fig. 1. The volume mean diameter is  $1.52 \mu\text{m}$ , and 40% of the volume is less than  $1.0 \mu\text{m}$ . A scanning electron micrograph of AI-850 particles is shown in Fig. 2, in which the surface of the microparticles appears relatively smooth, and the microparticles appear to be sphere-shaped. A transmission electron micrograph of cross-sections of AI-850 particles is shown in Fig. 3, where the bright white areas are the locations of the water-soluble excipients, the light gray areas are the locations of the paclitaxel, and the darker gray areas are the locations of the pores. Prior to reconstitution, the porosity of the AI-850 particles was predominantly internal.

Multiple analytical methods were evaluated as options for quantitative analysis of the particle size distribution of the paclitaxel particles within a reconstituted AI-850 suspension. Most of these methods (e.g., laser sizing methods) require large dilutions to obtain particle concentrations with the operating range of the respective detector, and as a result the AI-850-derived paclitaxel particles dissolved before analyses of such dilutions could be performed. A method for quantitative analysis was developed using a Coulter Multisizer II




Fig. 2. SEM of AI-850 dry powder particles.




Fig. 3. TEM of cross section of AI-850 dry powder particles.

run using electrolyte saturated with paclitaxel, which prevents the rapid dissolution of the AI-850-derived paclitaxel particles. The particle size distribution of the paclitaxel particles from a reconstituted AI-850 suspension analyzed on a Coulter Multisizer is shown in Fig. 4, with an observed volume mean particle size of  $2.0 \mu\text{m}$ . The Coulter Multisizer method used an aperture that could only detect particles down to  $1 \mu\text{m}$ . Thus, unlike the Malvern Mastersizer analysis of the AI-850 microparticles, which had a lower limit of detection of  $0.5 \mu\text{m}$ , the sub-micrometer particles were not detected with the Coulter Multisizer method, and the mean particle size value reported is an overestimation of the actual value. Attempts to perform suspension particle size analysis using a laser-based method on a Coulter LS230, which would have allowed for analysis of nano- and microparticles, using paclitaxel saturated media, were not successful due to problems attributed to the crystallization of paclitaxel within the paclitaxel-saturated media itself, affecting the LS230 analysis. An SEM image of paclitaxel particles isolated from a suspension post-reconstitution is shown in Fig. 5, which not only demonstrates the presence of microparticles of paclitaxel but also demonstrates that the microparticles themselves are internally porous, with significant surface porosity.

Paclitaxel dissolution for the parent bulk paclitaxel lot and for the average of 17 lots of AI-850 is shown in Fig. 6. These data illustrate that the process consistently produces a rapidly dissolving paclitaxel product.




Fig. 4. Coulter Multisizer particle size distribution of reconstituted AI-850.




Fig. 5. SEM of AI-850 particles post-reconstitution.

**Rat Pharmacokinetic Study**

Plasma pharmacokinetic data for rats dosed with AI-850 and Taxol are shown in Fig. 7 and Table I. AI-850 was well tolerated at all doses (5 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg of paclitaxel). Taxol administered as a 3-h infusion was also well tolerated at both dose levels (5 mg/kg and 10 mg/kg of paclitaxel). However, all the rats administered an i.v. bolus dose of Taxol at 10 mg/kg of paclitaxel died within 2 h.

**Rat Tissue Distribution Study**

Groups of rats were given an i.v. bolus dose of AI-850 (5.7 mg/kg of paclitaxel) or an i.v. bolus dose of Taxol (5.7 mg/kg of paclitaxel). Both an i.v. bolus dose of AI-850 (5.7 mg/kg of paclitaxel) and an i.v. bolus dose of Taxol (5.7 mg/kg of paclitaxel) were well tolerated. Data from selected time-points are shown in Table II, and tissue paclitaxel AUC values are shown in Table III.

**In Vivo Antitumor Efficacy**

To assess the efficacy of AI-850 in a tumor model, mice (young, adult female athymic NCr-Nu) were implanted subcutaneously (s.c.) with the human mammary tumor MDA-




Fig. 6. In vitro dissolution of paclitaxel from bulk paclitaxel (□) and AI-850 (▲). For AI-850, the error bars represent the standard deviation for 17 lots.

MB-435. Treatment began on day 14, when the median tumor size ranged from 108 to 144 mg (individual tumors ranging from 100 mg to 172 mg). The control tumors grew well, with a doubling time of approximately 10 days (200–400 mg). Agents were administered i.v. once a day for 5 days. Maximum weight losses observed were 4% for 15 mg/kg Taxol, and 0%, 9%, and 21% for AI-850 at 15 mg/kg, 30 mg/kg, and 40 mg/kg, respectively. Tumor weight data over time is shown in Fig. 8. At the 15 mg/kg dose, the time required for two tumor mass doublings was 59.6 days for Taxol and 56.9 days for AI-850, and the value of t-c was 44.4 days for Taxol and 41.7 days AI-850. For 30 mg/kg dose of AI-850, the time required for two tumor mass doublings was 66.4 days, and the value of




Fig. 7. Plasma paclitaxel concentrations in Sprague-Dawley rats. All values are means ± standard deviations for the combined data for male and female rats. (a) Treatment groups were Taxol Bolus at 5 mg/kg (▲) and 10 mg/kg (■). (b) Treatment groups were Taxol Infusion at 5 mg/kg (●) and 10 mg/kg (■). (c) Treatment groups were AI-850 Bolus at 5 mg/kg (○), 10 mg/kg (■), 20 mg/kg (▲), and 30 mg/kg (×).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.